NASDAQ:CMMB

Chemomab Therapeutics (CMMB) Stock Forecast, Price & News

$1.70

-0.03 (-1.73%)

(As of 06/5/2023 ET)

Compare

Today's Range: $1.63
▼
$1.76
50-Day Range: $1.42
▼
$1.84
52-Week Range: $1.38
▼
$5.35

Volume: 17,892 shs
Average Volume: 524,875 shs
Market Capitalization: $18.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Chemomab Therapeutics MarketRank™ Forecast

Analyst Rating: N/A
0.00 Rating Score
Upside/Downside: 311.8% Upside
$7.00 Price Target
Short Interest: Healthy
4.80% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.41
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.70) to ($1.20) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

766th out of 985 stocks

Pharmaceutical Preparations Industry

381st out of 483 stocks

2.0

Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of $7.00, Chemomab Therapeutics has a forecasted upside of 311.8% from its current price of $1.70.
Amount of Analyst Coverage
Chemomab Therapeutics has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.80% of the float of Chemomab Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Chemomab Therapeutics has a short interest ratio ("days to cover") of 5.7.
Change versus previous month
Short interest in Chemomab Therapeutics has recently decreased by 7.32%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Chemomab Therapeutics does not currently pay a dividend.
Dividend Growth
Chemomab Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CMMB.

2.4

News and Social Media Coverage

News Sentiment
Chemomab Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Chemomab Therapeutics this week, compared to 1 article on an average week.
Search Interest
3 people have searched for CMMB on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Chemomab Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.91% of the stock of Chemomab Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 34.80% of the stock of Chemomab Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Chemomab Therapeutics are expected to grow in the coming year, from ($1.70) to ($1.20) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Chemomab Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Chemomab Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Chemomab Therapeutics has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Chemomab Therapeutics (NASDAQ:CMMB) Stock

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Receive CMMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CMMB Stock News Headlines

June 5, 2023 | markets.businessinsider.com

Hemomab Therapeutics Reappoints Adi Mor As CEO; Sigal Fattal Reassumes Role Of CFO

June 5, 2023 | msn.com

Chemomab Therapeutics announces key management changes

June 6, 2023 | Altimetry (Ad)

Biden's latest bailout--terrible for America?

And a consultant for the Dept. of Defense (Joel Litman) says this is all leading to an event in the next 20 months that could help some get vastly wealthier… but also make it harder than ever to hang onto any money you make.This might be the most important development affecting you and your money over the next few years—

June 5, 2023 | finance.yahoo.com

Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update

June 2, 2023 | finance.yahoo.com

Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis

May 29, 2023 | americanbankingnews.com

Chemomab Therapeutics (NASDAQ:CMMB) versus Theratechnologies (OTCMKTS:THERF) Critical Comparison

May 24, 2023 | finance.yahoo.com

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

May 16, 2023 | finance.yahoo.com

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Q1 2023 Earnings Call Transcript

June 6, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

May 11, 2023 | finanznachrichten.de

Chemomab Therapeutics, Ltd.: Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update

May 11, 2023 | finance.yahoo.com

Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update

May 10, 2023 | americanbankingnews.com

Chemomab Therapeutics (CMMB) Set to Announce Quarterly Earnings on Thursday

April 26, 2023 | finance.yahoo.com

Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference

April 21, 2023 | americanbankingnews.com

Oppenheimer Weighs in on Chemomab Therapeutics Ltd.'s Q1 2024 Earnings (NASDAQ:CMMB)

April 19, 2023 | msn.com

Oppenheimer Maintains Chemomab Therapeutics (CMMB) Outperform Recommendation

April 18, 2023 | americanbankingnews.com

Chemomab Therapeutics (NASDAQ:CMMB) PT Lowered to $7.00

April 12, 2023 | finance.yahoo.com

Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update

March 31, 2023 | benzinga.com

Chemomab Therapeutics Stock (NASDAQ:CMMB), Guidance and Forecast

March 30, 2023 | msn.com

A Preview Of Chemomab Therapeutics's Earnings

March 30, 2023 | americanbankingnews.com

Chemomab Therapeutics (CMMB) Set to Announce Earnings on Friday

March 29, 2023 | finance.yahoo.com

Chemomab Therapeutics to Provide a Corporate Update on April 17, 2023

March 17, 2023 | finance.yahoo.com

Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update

March 6, 2023 | finance.yahoo.com

Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference

February 25, 2023 | marketwatch.com

Chemomab Therapeutics Shares Fall 16%, Hitting 52-Week Low

February 23, 2023 | morningstar.com

Chemomab Therapeutics stock soars after FDA clears IND for SSc treatment

February 23, 2023 | finance.yahoo.com

Is Chemomab Therapeutics (NASDAQ:CMMB) In A Good Position To Invest In Growth?

February 21, 2023 | marketwatch.com

Chemomab Therapeutics Climbs After FDA Clears Application for SSc Treatment

See More Headlines

CMMB Price History

30 days | 90 days | 365 days | Advanced Chart

CMMB Company Calendar

Last Earnings: 3/20/2023
Today: 6/06/2023
Next Earnings (Estimated): 8/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CMMB
CUSIP: N/A
CIK: 1534248
Web: www.chemomab.com
Phone: 972-77-331-0156
Fax: N/A
Employees: 20
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.00
High Stock Price Forecast: $7.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +311.8%
Consensus Rating: N/A
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.76)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-27,650,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -77.93%
Return on Assets: -67.79%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.83
Quick Ratio: 4.83

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.11 per share
Price / Book: 0.55

Miscellaneous

Outstanding Shares: 11,050,000
Free Float: 9,734,000
Market Cap: $18.79 million
Optionable: Not Optionable
Beta: 0.35

Key Executives

Dr. Dale R. Pfost Ph.D. (Age 65)
Chairman & CEO
Comp: $192k

Dr. Adi Mor George Ph.D. (Age 40)
Co-Founder, Chief Scientific Officer & Exec. Director
Comp: $480k

Mr. Donald R. Marvin MBA (Age 69)
CFO, Exec. VP & COO
Comp: $94k

Barbara Lindheim
Consulting VP of Investor & PR, Strategic Communications

Mr. Mitchell Lawrence Jones M.D.
Ph.D., VP of Corp. Devel. & Strategy

Dr. Matthew Frankel M.B.A.
M.D., Chief Medical Officer & VP of Drug Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CMMB Stock - Frequently Asked Questions

What is Chemomab Therapeutics' stock price forecast for 2023?: 0 analysts have issued 12 month price objectives for Chemomab Therapeutics' stock. Their CMMB share price forecasts range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next year. This suggests a possible upside of 311.8% from the stock's current price.
View analysts price targets for CMMB or view top-rated stocks among Wall Street analysts.
How have CMMB shares performed in 2023?: Chemomab Therapeutics' stock was trading at $3.20 at the beginning of 2023. Since then, CMMB shares have decreased by 46.9% and is now trading at $1.70.
View the best growth stocks for 2023 here.
Are investors shorting Chemomab Therapeutics?: Chemomab Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 422,900 shares, a decrease of 7.3% from the April 30th total of 456,300 shares. Based on an average trading volume of 74,000 shares, the days-to-cover ratio is presently 5.7 days. Currently, 4.8% of the shares of the stock are sold short.
View Chemomab Therapeutics' Short Interest.
When is Chemomab Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our CMMB earnings forecast.
How were Chemomab Therapeutics' earnings last quarter?: Chemomab Therapeutics Ltd. (NASDAQ:CMMB) released its quarterly earnings data on Monday, March, 20th. The company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($0.80) by $0.08.

What is Chemomab Therapeutics' stock symbol?: Chemomab Therapeutics trades on the NASDAQ under the ticker symbol "CMMB."
Who are Chemomab Therapeutics' major shareholders?: Chemomab Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Two Sigma Investments LP (0.27%) and Boothbay Fund Management LLC (0.24%). Insiders that own company stock include Dale R Pfost, Donald Marvin, George Adi Mor, Israel Gp Ltd Orbimed, Joel Michael Maryles and Neil Harris Cohen.
View institutional ownership trends.
How do I buy shares of Chemomab Therapeutics?: Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Chemomab Therapeutics' stock price today?: One share of CMMB stock can currently be purchased for approximately $1.70.
How much money does Chemomab Therapeutics make?: Chemomab Therapeutics (NASDAQ:CMMB) has a market capitalization of $18.79 million. The company earns $-27,650,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis.
How can I contact Chemomab Therapeutics?: Chemomab Therapeutics' mailing address is KIRYAT ATIDIM BUILDING 7, TEL AVIV L3, 6158002. The official website for the company is www.chemomab.com. The company can be reached via phone at 972-77-331-0156 or via email at arr@lifesciadvisors.com.

This page (NASDAQ:CMMB) was last updated on 6/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial